Liposomal Cytarabine-Daunorubicin CPX-351

A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposomal cytarabine-daunorubicin CPX-351 has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids. (NCI Thesaurus)

YOU MAY ALSO LIKE

Liposomal cytarabine

A form of the anticancer drug cytarabine that is contained inside very tiny, fat-like particles. It may have fewer side effects and…

Liposomal c-raf Antisense Oligonucleotide

The liposomal formulation of a c-raf-1 antisense oligonucleotide, with potential antineoplastic activity. Liposomal c-raf antisense oligonucleotide targets the translation initiation site of…

Liposomal Amphotericin B

A liposome-encapsulated formulation of the polyene antifungal antibiotic amphotericin B produced by the bacterium Streptomyces nodosus with antifungal activity. Amphotericin B binds…

Liposomal

A drug preparation that contains the active drug inside very tiny, fat-like particles. This form is easier for the body to absorb…

Liposarcoma of the Mouse Intestinal Tract

Large invasive neoplasm of adipose origin

Liposarcoma

A rare cancer of the fat cells.